Clinical Trials · NCT05537233
ADJUnct Semaglutide Treatment in Type 1 Diabetes
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Viral N. Shah
- Enrollment
- 115
- Start date
- Apr 2023
- Locations
- 4 sites, United States
- Primary endpoint
- Proportion of Adults With T1D Achieving Composite Outcome (CGM-measured Time in Range (TIR)>70% With Time Below Range (TBR) of <4% and Reduction in Body Weight by 5%) at 26 Weeks in the Semaglutide Group Compared to Placebo Group